Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) FCF Margin (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of FCF Margin data on record, last reported at 57.46% in Q3 2025.

  • For Q3 2025, FCF Margin rose 23123.0% year-over-year to 57.46%; the TTM value through Dec 2025 reached 224.31%, up 9007.0%, while the annual FY2025 figure was 224.31%, 9007.0% up from the prior year.
  • FCF Margin reached 57.46% in Q3 2025 per TNGX's latest filing, up from 1155.83% in the prior quarter.
  • Across five years, FCF Margin topped out at 42.53% in Q2 2021 and bottomed at 1155.83% in Q2 2025.
  • Average FCF Margin over 5 years is 427.46%, with a median of 328.1% recorded in 2021.
  • Peak YoY movement for FCF Margin: skyrocketed 36151bps in 2023, then plummeted -103544bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 307.87% in 2021, then tumbled by -39bps to 428.09% in 2022, then decreased by -13bps to 482.51% in 2023, then plummeted by -85bps to 893.15% in 2024, then skyrocketed by 94bps to 57.46% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 57.46% in Q3 2025, 1155.83% in Q2 2025, and 773.46% in Q1 2025.